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Background: Alternating administration of docetaxel and gemcitabine might result in improved time-to-treatment
failure (TTF) and fewer adverse events compared with single-agent docetaxel as treatment of advanced breast cancer.
Patients and methods: Women diagnosed with advanced breast cancer were randomly allocated to receive 3-
weekly docetaxel (group D) or 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G) until treatment
failure as ﬁrst-line chemotherapy. The primary end point was TTF.
Results: Two hundred and thirty-seven subjects were assigned to treatment (group D, 115; group D/G, 122). The
median TTF was 5.6 and 6.2 months in groups D and D/G, respectively (hazard ratio 0.85, 95% conﬁdence interval
0.63–1.16; P = 0.31). There was no signiﬁcant difference in time-to-disease progression, survival, and response rate
between the groups. When adverse events were evaluated for the worst toxicity encountered during treatment, there
was little difference between the groups, but when they were assessed per cycle, alternating treatment was
associated with fewer severe (grade 3 or 4) adverse effects (P = 0.013), and the difference was highly signiﬁcant for
cycles when gemcitabine was administered in group D/G (P < 0.001).
Conclusion: The alternating regimen was associated with a similar TTF as single-agent docetaxel but with fewer
adverse effects during gemcitabine cycles.
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introduction
Taxanes are effective in the treatment of advanced breast cancer
[1–3]. For docetaxel, response rates range from 34% to 64%,
and time-to-disease progression (TTP) is 6 months as ﬁrst-
line treatment [4–7].
Docetaxel administration not infrequently causes adverse
effects that may result in treatment discontinuation before
cancer progression [2, 5]. We hypothesised that alternating
docetaxel administration with a chemotherapy agent that has
a different side-effect proﬁle might result in a longer time-to-
treatment failure (TTF) than docetaxel monotherapy, and such
therapy might cause fewer adverse effects. We selected
gemcitabine as the agent to be alternated with docetaxel
because gemcitabine is relatively well tolerated and has activity
as monotherapy for advanced breast cancer [8, 9]. Efﬁcacy
of gemcitabine combined with either paclitaxel or docetaxel
compares well with taxane monotherapy as ﬁrst-line treatment
of advanced breast cancer [10, 11].
In the present study, we compared docetaxel monotherapy
with a regimen where docetaxel is alternated with gemcitabine
(D-G-D-G-D-G.) as ﬁrst-line treatments for advanced breast
cancer. To our knowledge, a similar trial has not been
conducted earlier.
patients and methods
study population
Women aged 70 years or younger with histologically conﬁrmed invasive
breast carcinoma were eligible, provided that they had measurable or
non-measurable distant metastases conﬁrmed histologically and/or
radiologically. Adjuvant chemotherapy, administered with or without
taxanes, was required to have been completed ‡6 months before enrolment.
Staging work-up included computed tomography or magnetic resonance
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analysis of blood cell counts and blood biochemistry.
Exclusion criteria included prior chemotherapy for metastatic disease,
World Health Organization (WHO) performance status (PS) of more than
two, history of cancer other than breast cancer, and any medical condition
that precluded administration of chemotherapy. Subjects with ascites or
pleural effusion as the sole manifestation of the disease and those with brain
or leptomeningeal metastases were excluded, as well as subjects with
metastatic lesions assessable by radionuclide scan only or with sclerotic
bone lesions as the only manifestation of the disease. Patients with impaired
liver function [serum bilirubin >1.5 ·N (times normal), alanine or
aspartate aminotransferase >3.0 ·N, alkaline phosphatase >5.0 ·N except in
the presence of bone disease and in absence of liver disorder] were not
eligible nor were those who had impaired renal function (serum creatinine
>1.5 · N), the blood neutrophil count <1.5 · 10
9/ml, platelet count <100 ·
10
9/ml, or haemoglobin level <100 g/l.
The study protocol (ClinicalTrials.gov identiﬁer NCT00191243) was
approved by an institutional ethics committee. Study participants provided
a written informed consent before entry.
treatments
The participants were randomly assigned (centrally with computer
concealing) to a study group in this open, prospective, phase III,
multicentre trial. At random assignment, the subjects were stratiﬁed
according to WHO PS (0 or 1 versus 2), prior exposure to taxanes in the
adjuvant setting, and the participating institution, and were allocated in
a 1:1 ratio to receive either docetaxel (Taxotere, Sanoﬁ-Aventis, Paris,
France) (group D) or docetaxel alternating with gemcitabine (Gemzar, Eli
Lilly, IN) (group D/G). Docetaxel, administered intravenously 100 mg/m
2
over 60 min, was given on day 1 of a 21-day cycle in both groups.
Gemcitabine 1000 mg/m
2 was administered as a 30- to 60-min
intravenous infusion on days 1 and 8 of a 21-day cycle in group D/G.
Following study protocol amendment (9 January 2003), the docetaxel
starting dose was reduced to 80 mg/m
2 in both groups to reduce the risk
of neutropenic infections. The number of chemotherapy cycles
administered was not limited.
Dexamethasone was given at times of docetaxel administration.
Prophylactic antibiotics or granulocyte colony-stimulating factors were
not recommended unless one or more episodes of febrile neutropenia or
severe infection occurred. Administration of trastuzumab at the standard
dosing was allowed for HER2-positive cancer [7, 12] and bisphosphonates
and palliative radiation therapy for patients with bone metastases.
After treatment failure, the scheduled second-line systemic therapy in
group D was single-agent gemcitabine administered as described above.
Second-line therapy was not deﬁned for patients assigned to the alternating
therapy. Selection of the later lines of therapy was at the discretion of the
treating physician. After completion of the protocol treatments, the study
participants were followed up at 3-month intervals until death or for
a minimum time period of 2 years.
study procedures
Blood cell counts and biochemistry were analysed before each cycle and
blood cell counts on cycle day 8. Adverse effects were graded according to
the National Cancer Institute Common Toxicity Criteria version 2.0 (http://
ctep.cancer.gov/reporting/ctc.html) and were collected on structured forms
on day 21 of each cycle. Tumour imaging was carried out at every third
cycle. Response to treatment was assessed during the study and centrally at
the completion of the study according to the RECIST criteria [13].
Chemotherapy doses were reduced when a nadir neutrophil count <0.5 ·
10
9/l persisted for ‡7 days or when febrile neutropenia occurred (fever
‡38.0 associated with neutrophil count <1.0 · 10
9/l). Docetaxel dose was
not reduced <60 mg/m
2. Whenever haematological recovery did not take
place before the next cycle was scheduled to begin, blood cell counts
were repeated weekly until the neutrophil count was ‡1.5 · 10
9/l and the
platelet count ‡100 · 10
9/l.
Treatment was considered to have failed when haematological recovery
did not take place within 6 weeks from day 1 of the prior chemotherapy
cycle, a nadir neutrophil count <0.5 · 10
9/l persisted for >7 days, febrile
neutropenia occurred at the docetaxel dose level of 60 mg/m
2, non-
haematological toxicity did not resolve to grade <3 within 3 weeks, in case
of anaphylaxis or ﬂuid retention of grade ‡3, or any treatment break
exceeded 6 weeks.
statistical analysis
TTF was preferred to TTP as the primary end point to account for both
unsatisfactory treatment efﬁcacy and toxicity as potential causes of
treatment failure. Disease progression, unacceptable toxicity, death, or
discontinuation of chemotherapy from any cause were considered
treatment failures. Secondary end points included response rate, response
duration, survival, treatment safety, and TTP.
The sample size (120 patients per group) was calculated assuming that
TTF, calculated from the date of initiation of chemotherapy to the date
of treatment failure, will be 20 and 36 weeks in groups D and D/G,
respectively, assuming a power of 0.80 and a signiﬁcance level of 0.05.
TTP was measured from the date of initiation of chemotherapy until the
date of progressive disease (PD) or death (whichever occurred ﬁrst) and
survival to the date of death. Duration of complete response (CR) and
partial response (PR) was measured from the date when CR or PR was
documented until the date of ﬁrst disease progression.
Frequency tables were analysed using the chi-square test or Fisher’s exact
test. Survival between groups was compared using the Kaplan–Meier
life-table method and the Cox proportional hazards model; the log-rank
test was used to conﬁrm effect consistency. Efﬁcacy analyses were based
on the intention-to-treat-principle. Subjects who received at least one
cycle of chemotherapy were included in safety analyses and those who
received ‡2 cycles for analysis of the response rate. When adverse events
were evaluated per cycle, a generalised estimating equations model for
repeated measurements was used [14]. The binary responses (event versus
no event) at each cycle were used as dependent variables, and the treatment
group, chemotherapy cycle, and the interaction between the treatment
group and the cycle were used as explanatory variables in the model. The
analysis was carried out with the GENMOD procedure of the SAS System.
P values are two-sided.
results
patient characteristics
Between 14 March 2002 and 20 September 2006, 240 subjects
were entered. Two hundred and thirty-seven subjects were
assigned to treatment: 115 to receive single-agent docetaxel
(group D) and 122 to docetaxel alternating with gemcitabine
(group D/G, Figure 1). One patient who did not receive the ﬁrst
chemotherapy dose was excluded from the efﬁcacy analyses
(group D). The allocation groups were balanced with respect of
the characteristics examined (Table 1).
treatment
A median of 8.0 chemotherapy cycles were administered in
both groups before treatment failure (range, 1 to 28).
Thirty-seven (82%) of the 45 patients assigned to a docetaxel
starting dose of 100 mg/m
2 had dose reduced during treatment
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with 106 (55%) of the 192 patients assigned to receive
80 mg/m
2 following study protocol amendment (group D,
54 out of 93; group D/G, 52 out of 99; P = 0.0009).
The mean docetaxel doses administered per cycle were similar
between the groups. The mean doses of gemcitabine
administeredrangedfrom919to952mg/m
2.Themostcommon
reasons for dose reduction were neutropenia and neutropenic
infections. Twenty-one (78%) of the 27 patients with HER2-
positive cancer assigned to group D and 15 (65%) of 23 such
patients assigned to group D/G received trastuzumab (P = 0.32).
efﬁcacy
The median follow-up time of the patients alive after
randomisation was 25 months on the date of database closure
on 15 May 2007 when the follow-up time of the last patient
entered exceeded 28 weeks. A total of 166 (70%) subjects had
failed treatment [group D, 85 (74%); group D/G, 81 (66%)],
the most common reasons being an adverse event [group D,
n = 46 (54%); group D/G, n = 35 (43%)] and progressive
cancer [group D, n = 34 (40%); group D/G, n = 36 (44%)].
The median TTF was 5.6 and 6.2 months in groups D and
D/G, respectively [hazard ratio (HR) 0.85, 95% conﬁdence
interval (CI) 0.63–1.16; P = 0.31], and similarly, TTP did not
differ signiﬁcantly between the groups (median, 11.7 versus
11.3 months, respectively; HR 1.05, 95% CI 0.79–1.41; P =
0.72). There was no difference in overall survival between the
groups (101 patients died; group D median, 28 months; group
D/G, 27 months; HR 1.11, 95% CI 0.75–1.64; P = 0.60;
Figure 2). Exploratory analyses of TTF stratiﬁed by WHO PS,
prior exposure to taxanes in the adjuvant setting, and HER2
expression indicated presence of no difference in TTF between
the treatments in these subgroups (supplemental Figure S1,
available at Annals of Oncology online).
Six (6%) patients in group D and 10 (9%) in group D/G
achieved CR as their best response, 63 (59%) and 57 (50%) PR,
27 (25%) and 38 (33%) stable disease (SD), and 10 (9%) and
10 (9%) PD, respectively. At central evaluation, 13% and 10%
-2 had abnormal liver
function
-1 had prior
 chemotherapy for BC
3 not assigned
to therapy
Group D Group D/G 
240 entered, no prior chemotherapy for
advanced breast cancer (BC), age <70 
237 were randomised
115 were assigned to
docetaxel 
122 were assigned to
docetaxel alternating
with gemcitabine  -1 was excluded from
efficacy analyses
Figure 1. The Consolidated Standards of Reporting Trials diagram of the
study.
Table 1. Patient and tumour characteristics at baseline
Characteristic Docetaxel
(n = 115)
Docetaxel alternating
with gemcitabine (n = 122)
Total
(N = 237)
Patient characteristics
Age, years
Median 55 54 55
Range 31–69 32–70 31–70
Time from primary diagnosis to randomisation, years
Median 5.0 3.4 4.0
Range 0.0–24.7 0.0–25.8 0.0–25.8
Time from ﬁrst diagnosis of distant metastases to randomisation, years
Median 0.1 0.1 0.1
Range 0.0–5.2 0.0–12.6 0.0–12.6
WHO performance status, n (%)
0 36 (31) 40 (33) 76 (32)
1 72 (63) 72 (59) 144 (61)
2 6 (5) 9 (7) 15 (6)
N.A. 1 (1) 1 (1) 2 (1)
Site of metastatic disease, n (%)
Bone 75 (65) 71 (58) 146 (62)
Liver 50 (44) 56 (46) 106 (45)
Lymph 44 (38) 40 (33) 84 (35)
Lung 39 (34) 39 (32) 78 (33)
Pleura 23 (20) 19 (16) 42 (18)
Skin 18 (16) 14 (12) 32 (14)
Other 17 (15) 15 (12) 32 (14)
Adjuvant chemotherapy, n (%)
Yes 61 (53) 70 (57) 131 (55)
No 54 (47) 52 (43) 106 (45)
Taxane as adjuvant chemotherapy, n (%)
Yes 7 (6) 14 (11) 21 (9)
No 108 (94) 108 (89) 216 (91)
Hormonal therapy before study entry
a, n (%)
Yes 67 (58) 64 (52) 131 (55)
No 48 (42) 58 (48) 106 (45)
Primary tumour characteristics
Histopathological type, n (%)
Ductal 90 (78) 87 (71) 177 (75)
Lobular 19 (17) 27 (22) 46 (19)
Other 5 (4) 6 (5) 11 (5)
N.A. 1 (1) 2 (2) 3 (1)
Histological grade, n (%)
Grade 1 12 (10) 12 (10) 24 (10)
Grade 2 47 (41) 53 (43) 100 (42)
Grade 3 45 (39) 42 (34) 87 (37)
N.A. 11 (10) 15 (12) 26 (11)
ER, n (%)
Positive 82 (71) 90 (74) 172 (73)
Negative 29 (25) 32 (26) 61 (26)
N.A. 4 (4) 0 (0) 4 (2)
PR, n (%)
Positive 67 (58) 80 (66) 147 (62)
Negative 43 (37) 42 (34) 85 (36)
N.A. 5 (4) 0 (0) 5 (2)
HER-2, n (%)
Positive 27 (24) 23 (19) 50 (21)
Negative 66 (57) 86 (71) 152 (64)
N.A. 22 (19) 13 (11) 35 (15)
aIncludes hormonal therapy administered in the adjuvant setting and/or for
advanced disease
WHO, World Health Organization; N.A., not available; ER, estrogen
receptor; PR, progesterone receptor; HER-2, erbB2 tyrosine kinase receptor
[positive: either immunohistochemistry strongly positive (+++)o ra nin
situ hybridisation test positive].
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71% and 65% PR, 13% and 22% SD, and 3% and 3% PD.
The objective response rate (CR + PR) did not differ between
groups D and D/G, regardless of whether it was assessed by in-
house investigators (65% versus 58%, respectively; P = 0.30) or
centrally (84% versus 75%; P = 0.15). The duration of objective
response did not differ between the groups (D, 10.9 months
versus D/G, 12.9 months; HR 0.85, 95% CI 0.57–1.28; P = 0.44).
treatment tolerability
Grade 3 or 4 haematological adverse effects occurred in 99% and
96% of patients allocated to group D and D/G, respectively (P =
0.21), and 61% and 55% had grade 3 or 4 non-haematological
adverse events (P = 0.34). Patients allocated to docetaxel had
more frequently grade 3 or 4 dyspnoea (21%) than those
allocated to alternating chemotherapy (10%; P = 0.015; Table 2).
One chemotherapy-related death was recorded in group D.
When adverse events were evaluated per cycle instead of
assessing the worst toxicity encountered during the entire
treatments, alternating treatment was associated with fewer
severe adverse effects (P = 0.013; amenorrhoea was excluded
from the analyses). The difference was highly signiﬁcant for
even-numbered cycles (when gemcitabine was administered in
group D/G; P < 0.001) but not for odd-numbered cycles (when
docetaxel was administered in both groups; P = 0.09). Both
severe haematological and non-haematological adverse effects
were less in group D/G during gemcitabine cycles.
second-line gemcitabine
Forty-ﬁve (39%) subjects assigned to group D received
gemcitabine as second-line treatment. Five (11%) of the 44
assessable patients achieved a PR. Thirteen (30%) failed due
to adverse events (most commonly infection) and 14 (32%)
due to PD; 17 had gemcitabine discontinued at PR or SD
after a median of 5.5 months of treatment.
discussion
The study failed to demonstrate that alternating two single-
agents (docetaxel and gemcitabine) with different toxicity
proﬁles leads to a longer TTF than administration of docetaxel
alone. Patients who received the alternating therapy had
a similar frequency of serious adverse events as those who
received docetaxel when the worst toxicity encountered
during the entire treatment was considered, but they had fewer
serious events when toxicity was analysed per cycle of
chemotherapy administered.
Regimens where single-agent taxane is alternated with
another single-agent [15, 16] or combination therapy [17] have
rarely been evaluated as treatments of advanced breast cancer.
Two prospective randomised trials have compared docetaxel
alternating with doxorubicin to the same agents administered
in a sequence [15, 16]. Both trials differed from the present
study in several key aspects: the number of chemotherapy cycles
was limited to a maximum of eight, the primary end point
Figure 2. Time-to-treatment failure (A), time-to-disease progression (B), and overall survival (C).
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small. Both trials found no signiﬁcant difference in the CR
rates (range, from 2% to 14%), response rates (range, from
52% to 67%) and the TTP (range, from 7.6 to 9.0 months)
between the alternating and the sequential treatments.
The present study has some limitations. A clinically
signiﬁcant difference in the TTF might have been missed due to
the study size. Yet, we found no trend in the TTF in favour
of either treatment with the current sample size indicating
that the size of the undetected difference, if any, is likely small.
We did not assess quality of life, which might have differed
between the groups. The study protocol recommended
single-agent gemcitabine as the second-line treatment following
docetaxel failure in group D, but only 39% of these patients
received it probably due to investigator preference to
administer other agents following taxane failure.
We conclude that alternating administration of docetaxel
with gemcitabine as ﬁrst-line systemic chemotherapy for
metastatic breast cancer did not result in a longer TTF
compared with single-agent docetaxel, but adverse effects were
generally fewer during the gemcitabine cycles.
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